NCT05805501 2026-02-12
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Hoffmann-La Roche
Phase 2 Active not recruiting
Clinical Trials
5 trialsNCT05017012 2026-01-08
MK-3475A-C18
Merck Sharp & Dohme LLC
Phase 1 Active not recruiting
NCT04522323 2025-07-25
A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
MedImmune LLC
Phase 1 Active not recruiting
NCT05059522 2025-06-25
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Pfizer
Phase 3 Active not recruiting
NCT05256472 2025-03-06
A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma
Akeso
Phase 2 Active not recruiting